BioCentury on BioBusiness,
Emerging Company Profile
Seragon picks up Aragon's SERD assets in breast cancer after J&J acquisition
Related tables, figures and sidebars
Seragon: Succeeding Aragon
Monday, January 13, 2014
Pharmaceuticals Inc. is picking up where its predecessor Aragon
Pharmaceuticals Inc. left off after Johnson
& Johnson acquired the company for its androgen receptor
antagonists. The Aragon spinout raised $30 million in a series A round last
October and is using the funds to develop oral small molecules that both block
estrogen receptors and induce their degradation.
The company said it will
initially focus on advancing its Selective Estrogen Receptor Degraders (SERDs)
program in ER-positive metastatic breast cancer patients who have failed
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]